Last reviewed · How we verify
Placebo (for galantamine)
Placebo produces no pharmacological effect and serves as an inert control in clinical trials.
Placebo produces no pharmacological effect and serves as an inert control in clinical trials. Used for Control arm in clinical trials for Alzheimer's disease (as comparator to galantamine).
At a glance
| Generic name | Placebo (for galantamine) |
|---|---|
| Also known as | Placebo |
| Sponsor | University of Sao Paulo |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inactive substance used as a comparator in randomized controlled trials to assess the efficacy of active drugs like galantamine through blinded study designs. It relies on the placebo effect—the therapeutic benefit arising from patient expectation and the clinical trial context rather than any intrinsic pharmacological activity. This allows researchers to isolate the true drug effect from psychological and contextual factors.
Approved indications
- Control arm in clinical trials for Alzheimer's disease (as comparator to galantamine)
Common side effects
Key clinical trials
- Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment (PHASE2)
- Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans (PHASE1, PHASE2)
- Effect of Galantamine on Inflammation and Cognition (PHASE2)
- Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL) (PHASE4)
- Galantamine and CBT4CBT Pilot to Prevent Relapse. (EARLY_PHASE1)
- Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia (PHASE2)
- Subarachnoid Hemorrhage Recovery And Galantamine (PHASE1, PHASE2)
- Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for galantamine) CI brief — competitive landscape report
- Placebo (for galantamine) updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI